Article
ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
Clinical lung cancer - 1 Mar 2015
Boyle Theresa A, Masago Katsuhiro, Ellison Kim E, Yatabe Yasushi, Hirsch Fred R
Abstract excerpt
BACKGROUND: ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung adenocarcinoma with ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the standard diagnostic procedure for detecting ROS1 rearrangements, we studied immunohistochemistry...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
